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Mental retardation (MR) is a nonprogressive condition characterized by a significant impairment of intellectual
capabilities with deficit of cognitive and adaptive functioning and onset before 18 years. Mental retardation
occurs in about 2 to 3% of the general population and it is estimated that 25 to 35% of the cases may be due to
genetic causes. Among these ‘‘genetic’’ MR, 25 to 30% are probably due to mutations in a gene on the X
chromosome (X-linked mental retardation, XLMR). Given the genetic heterogeneity of XLMR, the availability
of a considerable number of patients with accurate phenotypic classification is a crucial factor for research. The
X-linked Mental Retardation Italian Network, which has been active since 2003, has collected detailed clinical
information and biological samples from a vast number of MR patients. Collected samples and clinical
information are inserted within the XLMR bank, a comprehensive molecular and clinical web-based database
available at the address http://xlmr.unisi.it. The database is organized in three distinct parts. Part I and II contain
several electronic schedules to register information on the family, the phenotypic description, the photographs,
and a 20 sec movie of the patient. Part III allows the registration of molecular analyses performed on each case;
samples and clinical data are usable via password-restricted access. Clinical and molecular centers interested
in joining the network may request a password by simply contacting the Medical Genetics of the University
of Siena. The XLMR bank is an innovative biological database that allows the collection of molecular and
clinical data, combines descriptive and iconographic resources, and represents a fundamental tool for
researchers in the field of mental retardation. Hum Mutat 28(1), 13–18, 2007. r 2006 Wiley-Liss, Inc.
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INTRODUCTION
Mental retardation (MR) is a nonprogressive condition
characterized by a significant impairment of intellectual capabil-
ities with deficit of cognitive and adaptive functioning and onset
before 18 years [Chelly and Mandel, 2001]. General intellectual
functioning is defined by the intelligence quotient (IQ) and
adaptive functioning refers to how individuals deal with common
life demands. Mental retardation occurs in about 2 to 3% of the
general population [Gecz, 2004] and represents an important
socioeconomic and medical issue, given that MR patients need
a continuous support from families and healthcare operators. It is
estimated that a percentage of MR cases between 25% and 35%
may be due to genetic causes. On the basis of the IQ value, mental
retardation may be classified in four categories of severity:
mild (IQ 50–70), moderate (IQ 35–50), severe (IQ 20–35), and
profound (IQo20). Moreover, MR may be present in association
with other clinical manifestations (syndromic MR) or may be
isolated (nonsyndromic MR) [Mulley et al., 1992]. Males are more
frequently affected than females, with an excess of about 30%
of male cases explained by the presence of several causative genes
on the X chromosome responsible for the X-linked cases of MR
(XLMR) [McLaren and Bryson, 1987; Baird and Sadovnick, 1985;
Neri and Chiurazzi, 1999]. At present, 27 genes for nonsyndromic
and 45 genes for syndromic XLMR are known [Renieri et al.,
2005; Bauters et al., 2005]. Some genes are responsible for both
syndromic and non-syndromic XLMR and most of them are
responsible for a very low percentage of cases, comprising between
0.1 and 1%.
The large number of known XLMR genes and the fact that
no major genes exist makes it difficult to offer a molecular
diagnosis to MR patients. Given the genetic heterogeneity of
XLMR, the availability of a considerable number of patients with
accurate phenotypic classification is a crucial factor for research.
The X-linked Mental Retardation Italian Network includes 12
laboratories and 27 clinical centers and has been active since
2003, collecting MR patients with detailed clinical information
according to common criteria and analyzing known XLMR genes.
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It collects both sporadic and familial mentally retarded male
patients negative for Fragile X Mental Retardation Syndrome
(FRAXA), chromosomal and subtelomeric rearrangements. Bio-
logical samples are conserved in a biobank located at the Medical
Genetics laboratory of the University of Siena and at the Genetic
Institute of the Universita` Cattolica del Sacro Cuore in Rome.
Collected samples and clinical information are inserted in a web-
based database available at the address http://xlmr.unisi.it through
a password-restricted access. All centers interested in joining the
Network can contact the Medical Genetics of the University of
Siena.
We describe here the ‘‘XLMR bank,’’ a comprehensive web-
based database that includes accurate clinical and molecular data
on the MR patients present in the biobank. Samples and clinical
data are available upon request for specific studies. The XLMR
bank represents an important tool for researchers involved in the
discovery of the molecular genetic bases of autosomal and X-linked
MR and the clarification of the pathogenic processes that underlie
the disease.
THE XLMR BANK
The XLMR bank is available at the web address http://
xlmr.unisi.it and it is maintained and updated on a server at the
University of Siena. The database was created using Access soft-
ware (Microsoft Office, Microsoft; www.microsoft.com) for data
management. The website is written in Virtual Basic script
(VBScript) and it takes advantage of a Microsoft Internet Infor-
mation Server (IIS) with Active Server Pages (ASP) technology.
Database Structure
The home page of the XLMR bank (http://xlmr.unisi.it/home-
page.asp) contains general information about the project. In
particular, it explains the aims and the overall organization of the
project (clinical centers and laboratories involved, patients
enrolled, and genes analyzed). Using the ‘‘Search’’ option, external
users can visualize the complete list of patients and pedigree and
provisional or definitive diagnosis for each patient (Fig. 1).
The overall design of the XLMR bank database includes three
distinct parts with password-restricted access (Supplementary
Figure S1; available online at http://www.interscience.wiley.com/
jpages/1059-7794/suppmat). Each part is organized in several
electronic schedules, to collect detailed clinical and molecular
data. Part I includes forms filled by the clinical center that has
visited the patient and collected the biological samples (Fig. 2).
The forms are divided in the following specific sections: 1) private
data; 2) family history (pedigree, clinical data, and relatives’
photographs); 3) anamnestic form (clinical history of the patient,
IQ value, adaptive functioning evaluation and behavioral tests,
laboratory results for standard cytogenetic analysis, investigation
of subtelomeric rearrangements, and fragile-X test); 4) clinical
data of the patient (clinical features, morphologic examination,
neurological data, JPEG format photographs, and 20 sec movie
FIGURE 1. Home page of the XLMR bank (http://xlmr.unisi.it). Using the ‘‘Search’’ option available at the home page, users can
visualize the complete list of patients recorded in the bank and consult their pedigree. This set of information is available also
for ‘‘external users’’without password access. [Color ¢gure can be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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whenever relevant); 5) privacy (name and address of the physician
that retains the informed consent); 6) diagnosis (provisional
diagnostic hypothesis); 7) trait description, using conventional
dysmorphology dictionary (from London Dysmorphology[LDDB]
and Possum databases); 8) shipped biological samples (collected
samples and biobank address). To guarantee confidentiality, each
sample in the database is univocally identified by a code of three
numbers separated by an hyphen: a progressive number generated
by the system that characterizes the family and is the same for each
family member and two numbers indicating pedigree position of
the subject (Fig. 2I).
Part II is completed by biobank curators and it includes
information on the source and the type of stored biological samples
(Fig. 3). Currently, the following biological samples are stored:
DNA, plasma, and lymphocytes and lymphoblastoid cell lines in
dimethyl sulfoxide (DMSO) medium.
Part III includes information on laboratory tests performed on
each sample (Fig. 4). This part is completed by the laboratories
that join the Network and execute the molecular analyses. The
laboratory tests currently performed are listed in Table 1.
DatabaseAccessibility and Clinical and Molecular
Data Management
The database is organized on five levels of admittance, a public
level and four different ‘‘participant’’ levels, accessible through
a password only to centers belonging to the ‘‘X-linked Mental
Retardation Italian Network’’ (Supplementary Figure S1). The
first level is freely available to external users going to the ‘‘Search’’
option. External users can freely visualize the pedigree of each
case. Specific information is accessible only for participants
through a ‘‘Log in’’ page, which includes detailed clinical data,
location, and preservation of biological samples (DNA, lympho-
blastoid cell lines, plasma, urine samples, etc.) and molecular data.
A second level password is assigned to clinical centers that visit
the patient and decide to insert the case into the XLMR bank.
Clinical centers collect biological samples and send them to the
laboratories qualified for storage. A laboratory qualified for storage
has to guarantee the establishment and maintenance of lympho-
blastoid cell lines. Using the second level password, clinical centers
can visualize and modify clinical data limited to patients they have
inserted and they can consult but not modify their molecular data.
A third level password allows to clinical centers to visualize clinical
and molecular data of all patients in the bank. Laboratories that
perform molecular analyses have a fourth level password that
allows them to complete Part III of the database. Each laboratory
can visualize molecular information inserted by other laboratories.
The fifth level password is the administrator level. Only bank
curators have this access, which allows users to visualize and
modify all the information maintained in the database, including
anagraphical data.
Security and Quality Assurance
The database has been constructed in compliance with the
guidelines of the Italian Society of Human Genetics and Telethon
FIGURE 2. Part I of the XLMR bank database. A: Access to this section is password-restricted. B^I:The di¡erent schedules included
in this section and ¢lled in by the clinical center that has visited the patient. [Color ¢gure can be viewed in the online issue,which is
available at www.interscience.wiley.com.]
HUMANMUTATION 28(1),13^18,2007 15
Human Mutation DOI 10.1002/humu
Foundation for biobanking [Dagna Bricarelli et al., 2003].
The database design assures patients’ anonymity, privacy and
confidentiality, according to international criteria [Godard et al.,
2003]. Moreover, the informed consent has been written explicitly
stating all aspects of stored samples and personal data management
[Godard et al., 2003].
The XLMR bank is available to all users who contact bank
curators and fill in and sign a specific form asking to join the
Network on X-Linked Mental Retardation and to receive a new
password. The Network members agree to follow the rules of the
bank and commit themselves not to distribute the password
and the information maintained in the database. Anonymity of the
samples is assured in each step of the research. Only the bank
curator has access to the whole information content of the
database, including personal data. Neither other members of the
Network nor external investigators wishing to take advantage from
stored samples can access patients’ personal data (anagraphical
data, photographs, movies, etc.) and consequently they are not
able to identify individuals. Only clinicians with a second level
password can visualize personal data limited to patients they
enrolled in the database.
Both genomic DNA and lymphoblastoid cell lines (or primary
lymphocytes for future cell line establishment) are stored for all
probands and for available relatives. DNA aliquots for standard
analyses by different network laboratories are prepared immedi-
ately upon DNA extraction. Subsequently, two aliquots of at least
400 mg each are prepared and they are stored in–201C freezers for
long-term conservation. Regarding cell cultures, six distinct
aliquots for each lymphoblastoid cell line are stored (four aliquots
in the–1351C freezer and two in the liquid nitrogen Dewar). Cells
are frozen at passage 2 in 1.5–2  107 cells/ml aliquots. To
prevent the accidental damage of samples, storage of biological
materials is organized in different–201C or–1351C freezers.
Database Functions
Users that visit the online database can search for a patient by
simply looking through the list of registered cases. Alternatively,
the database may be explored using the ‘‘Search’’ option available
after login. The search page allows to browse the database
selecting for any field the user wants to search for (Supplementary
Figure S2). It is possible to search by a single field or to combine
two or more fields. As a result of the search, the user will visualize
the list of patients that present the selected feature(s). Information
on the selected patients will be available according to the level of
the login password.
DISCUSSION
The primary focus of the XLMR bank is to collect a wide
number of both syndromic (unknown syndromes) and nonsyn-
dromic mental retardation cases. Familial cases with an X-linked
pattern of transmission are preferred. However, the bank collects
FIGURE 3. Part II of the XLMR bank database.This section of the database includes information on the source and the type of stored
biological samples. It is possible to add new samples simply by clicking on the check-box corresponding to the correct sample type
stored (i.e., DNA sample). Note that the code is generated by the systemwhen a new patient is registered in the bank.The same code
is attributed to each sample obtained from that patient. [Color ¢gure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
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also sporadic cases in which the proband is a male. After the first
2 years, 56 familial, nine likely familial, and 81 sporadic cases have
been inserted in the database.
An innovative feature of this biological database is the accuracy
of clinical data collection using a combination of descriptive
and iconographic tools: text areas, JPEG format photographs, and
20 sec movies. The availability of a detailed description will allow a
better definition of the phenotype, since patients with the
molecular defect will be identified; this may help researchers in
the characterization and definition of new syndromes.
Given that part of the laboratories involved in the project
have expertise in lymphoblastoid cell lines culture and DNA
storage procedures, a characteristic of the biobank described here
is the absence of a main center for the storage of biological
samples. All participating laboratories able to establish lympho-
blastoid cell lines may propose to store some of the samples.
Requirements that a laboratory candidate for biobanking activities
must guarantee are those established by the referral guidelines
[Godard et al., 2003]. In our opinion these collaborative efforts
permit a better use of resources due to a distribution of laboratory
costs and operators working time. After the first 2 years of activity,
approximately 70% of biological samples are stored in Siena and
30% in Rome.
A truly collaborative effort has been made to collect detailed
molecular data about each patient. For this aim, mutation
analysis is performed on all patients for all genes in study. Linkage
analysis for families with at least three affected individuals
FIGURE 4. Part III of the XLMR bank database. Each panel of this section includes information on the laboratory tests performed
on collected samples. Note that di¡erent testsmay be added or deleted on the basis of the ongoingwork. [Color ¢gure can be viewed
in the online issue,which is available at www.interscience.wiley.com.]
TABLE 1. Laboratory Tests Currently Executed by theXLMR
ItalianNetworkMembers
Mutation analysis Gene name Laboratory
MECP2 Lecco
OPHN1 Lecco
FMR2 Padova
NLGN3/NLGN4 Pavia
DCX Pisa
ARX Roma
IL1RAPL1 Roma
AGTR2 Trieste
ATRX Troina
PQBP1 Troina
RSK2 Troina
Enzymatic/biochemical
assays
Assay Laboratory
Blood creatine
dosage
Firenze,
Genova
FACL4 activity Siena
RSK2 activity Siena
Linkage analysis Intervals Laboratory
Xq12^13 Troina
Xq21^22 Roma
Xq22^24 Siena
Xq26^28 Milano
Array-CGH Analysis Laboratory
Whole genome Pavia, Siena,
Troina
X chromosome Siena
Other tests Test Laboratory
X-inactivation Milano
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in two generations and exclusion/compatibility mapping for
smaller families are performed. Finally, we perform array-based
comparative genomic hybridisation (CGH) in all enrolled patients
to investigate segmental submicroscopic aneuploidies.
The XLMR bank is an ongoing dynamic database. New clinical
centers and laboratories can join the Network at any time just by
requesting an appropriate level password from the bank curator.
This flexibility allows to meet the demands deriving from scientific
knowledge.
Each newly identified mental retardation gene could be added
to the list of the molecular tests performed, as soon as a laboratory
becomes available. At the same time, the members of the Network
may decide to stop the analysis of genes for which the testing is
of unproven utility according to the scientific community.
A clinical center may ask for the appropriate level password
just to include a single family or a single patient in the database.
This allows a more comprehensive collection of interesting cases
that have been seen also in small clinical centers spread overall Italy.
To our knowledge the XLMR bank is a unique resource that
combines molecular data with accurate clinical information. The
XLMR bank with the biobank service and the collection of
detailed clinical information represents an important tool for
researchers in the field of mental retardation. The availability
for the scientific community of biological samples and clinical
information from our bank may help in the identification of new
mental retardation causative genes and in the delineation of
new syndromes.
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APPENDIX: A
The XLMR Italian Network members are: Amoroso A.
(Universita` di Torino, Italy), Bassi M.T. (IRCSS E. Medea, Bosisio
Parini, Italy), Battaglia A. (Istituto Stella Maris, Pisa, Italy),
Bedeschi M.F. (Clinica Mangiagalli, Milano, Italy), Bigoni S.
(Universita` di Ferrara, Italy), Borgatti R. (IRCSS E. Medea,
Bosisio Parini, Italy), Carnevale F. (P.O. Giovanni XXIII, Bari,
Italy), Caruso U. (Istituto Gaslini, Genova, Italy), Cavalli P.
(Istituti Ospitalieri, Cremona, Italy), Chiurazzi P. (UCSC, Roma,
Italy), D’Alessandro E. (Universita` dell’Aquila, Italy), D’Avanzo
G. (A.O. S.G. Moscati, Avellino, Italy), De Marchi M. (Universita`
di Torino, Italy), Di Rocco M. (Istituto Gaslini, Genova, Italy),
Faravelli F. (Ospedale Galliera, Genova, Italy), Ferrero G. (Ospe-
dale Regina Margherita, Torino, Italy), Fichera M. (IRCCS Oasi,
Troina, Italy), Fischetto R. (P.O. Giovanni XXIII, Bari, Italy),
Galasso C. (Universita` Tor Vergata, Roma, Italy), Garavelli L.
(Arcispedale S. Maria Nuova, Reggio Emilia, Italy), Guerrini R.
(Istituto Stella Maris, Pisa, Italy), Hladnik U. (IRCCS Burlo
Garofolo, Trieste, Italy), La Marca G. (Ospedale Meyer, Firenze,
Italy), Lerone M. (Istituto Gaslini, Genova, Italy), Marchina E.
(Universita` di Brescia, Italy), Mazzanti L. (Ospedale S. Orsola,
Bologna, Italy), Memo L. (USSL9, Treviso, Italy), Micheli V.
(Universita` di Siena, Italy), Moro F. (Istituto Stella Maris, Pisa,
Italy), Murgia A. (Universita` di Padova, Italy), Neri G. (UCSC,
Roma, Italy), Pantaleoni C. (Istituto Besta, Milano), Pergola E.M.
(USL RME, Roma, Italy), Priolo M. (Ospedali Riuniti, Reggio
Calabria, Italy), Rinaldi M.M. (Ospedale Cardarelli, Padova, Italy),
Rinaldi R. (Ospedale S. Camillo, Roma, Italy), Romano C.
(IRCCS Oasi, Troina, Italy), Russo S. (Istituto Auxologico
Italiano, Milano), Scarano G. (A.O.R.N., G. Rummo, Benevento,
Italy), Selicorni A. (Clinica Pediatrica De Marchi, Milano, Italy),
Sestini S. (Universita` di Siena, Italy), Stangoni G. (Ospedale di
Assisi, Assisi, Italy), Strisciuglio P. (Ospedale Pugliese, Catanzaro,
Italy), Tenconi R. (Universita` di Padova, Italy), Toniolo D. (DIBIT,
Milano, Italy), Turolla L. (USSL, Treviso, Italy), Verri A. (IRRCS
C. Mondino, Pavia, Italy), Zammarchi E. (Ospedale Meyer,
Firenze, Italy), Zelante L. (IRCSS S. Giovanni Rotondo, Italy),
and Zuffardi O (Universita` di Pavia, Italy).
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